Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | 3004171 | PO / MO |
The patient took third dose of Vivotif on third day after the first dose and fourth dose on fourth day after the first dose; Case reference number US-BN-2025-000911 is a spontaneous case initially received from other health care professional via Communication (reference number: USBAV25-1034) on 06-May-2025 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 30-Apr-2025 also reported as day zero, the patient took first dose of Vivotif (batch number: *3004171; expiration date: Aug-2025) one tablet* orally, for indication reported as vaccination.* On 02-May-2025 also reported as day two, two days after the first dose, the patient took the second dose of Vivotif (batch number: *3004171; expiration date: Aug-2025) one tablet* orally. On 03-May-2025, also reported as day three, three days after the first dose, the patient took the third dose of Vivotif (batch number: *3004171; expiration date: Aug-2025) one tablet* orally (explicitly coded as 'inappropriate schedule of vaccine administered). On 04-May-2025, also reported as day four, four days after the first dose, the patient took fourth dose of Vivotif (batch number: *3004171; expiration date: Aug-2025) one tablet* orally (explicitly coded as 'inappropriate schedule of vaccine administered). At the time of the *follow-up* report, it was *reported that the patient did not experience* any adverse event due to Vivotif. Additional information received from health care professional via Communication (reference number: USBAV25-1041) on 06-May-2025. New information included new reporter added, dates of vaccinations. Additional information received from health care professional via Communication (reference number: USBAV25-1049) on 07-May-2025. New information included patient age and conformation on days when Vivotif was taken. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up received from a health care professional on 18-Jun-2025: New information included patient details, dosing information and confirmation that the patient did not experience any adverse event due to Vivotif.; Reporter's Comments: An 18-year-old male patient took the third dose of Vivotif on the day 3 after the first dose and the fourth dose of Vivotif on the day 4 after the first dose, which is considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An 18-year-old male patient took the third dose of Vivotif on the day 3 after the first dose and the fourth dose of Vivotif on the day 4 after the first dose, which is considered as inappropriate schedule of vaccine administered. The patient did not experience any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE